	US 11,702,458 B2
	PD1-41BBL fusion protein and methods of use thereof
Mark L. Tykocinski, Merion Station, PA (US); Noam Shani, Zikhron-Yaakov (IL); Yosi Gozlan, Rehovot (IL); Michal Dranitzki Elhalel, Shoresh (IL); Edwin Bremer, Groningen (NL); and Ido Kaminsky, Ramat-Gan (IL)
Assigned to KAHR Medical Ltd., Modiln Makabim-ReUt (IL)
Appl. No. 16/475,705
Filed by KAHR Medical Ltd., Jerusalem (IL)
PCT Filed Jan. 4, 2018, PCT No. PCT/IL2018/050015 § 371(c)(1), (2) Date Jul. 3, 2019, PCT Pub. No. WO2018/127917, PCT Pub. Date Jul. 12, 2018.
Claims priority of provisional application 62/442,471, filed on Jan. 5, 2017.
Prior Publication US 2019/0352371 A1, Nov. 21, 2019
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 14/705 (2006.01); A61K 38/17 (2006.01); A61P 35/00 (2006.01); C07K 19/00 (2006.01); C07K 16/24 (2006.01); C07K 16/28 (2006.01)

CPC C07K 14/70503 (2013.01) [C07K 14/70575 (2013.01); C07K 16/241 (2013.01); C07K 16/2827 (2013.01); C07K 2319/21 (2013.01)]

24 Claims

1. A PD1-41BBL fusion protein in a form of a homo-trimer comprising a PD1 amino acid sequence capable of binding PD-L1 and a 41BBL amino acid sequence capable of binding 41BB, wherein said PD1 amino acid sequence is as set forth in SEQ ID NO: 2 or at least 123 amino acids in length fragment thereof.